Picture of Natco Pharma logo

NATCOPHARM Natco Pharma News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareBalancedMid CapHigh Flyer

REG - JSC NatCo Kaz.Temir - Tender Offer - Notice

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220929:nRSc2207Ba&default-theme=true

RNS Number : 2207B  JSC Nat.Co. Kazakhstan Temir Zholy  29 September 2022

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON
LOCATED OR RESIDENT IN, ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE,
PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT OR THE TENDER OFFER AND CONSENT
SOLICITATION MEMORANDUM.

29 September 2022

JOINT STOCK COMPANY "NATIONAL COMPANY "KAZAKHSTAN TEMIR ZHOLY"

NOTICE TO NOTEHOLDERS IN CONNECTION WITH THE TENDER OFFER AND CONSENT
SOLICITATION IN RESPECT OF ITS U.S.$1,100,000,000 6.950% Guaranteed Notes due
2042 (ISIN (REG S): XS0799658637; ISIN (RULE 144A): US48667DAD66; CUSIP (RULE
144A): 48667 DAD6)

ERRATUM NOTICE:

 

Noteholders are advised that the Notice of Meeting dated 27 September 2022
(the "Notice of Meeting") (including the Form of Notice of Meeting appended to
each of the Launch Announcement dated 27 September 2022 (the "Launch
Announcement") and the Tender Offer and Consent Solicitation Memorandum dated
27 September 2022 (the "Tender Offer and Consent Solicitation Memorandum")),
which was released to the Noteholders via RNS and the clearing systems,
includes an erroneous reference under the heading "Voting and Participation
Deadlines" (on page 5 of the Notice of Meeting, p13 of the Launch Announcement
and p44 of the Tender Offer and Consent Solicitation Memorandum) stating the
Expiration Deadline as 26 September 2022. Such Expiration Deadline shall
instead be 26 October 2022 (as stated elsewhere in the Launch Announcement and
the Tender Offer and Consent Solicitation Memorandum).

 

This Notice is given by:

JOINT STOCK COMPANY "NATIONAL COMPANY "KAZAKHSTAN TEMIR ZHOLY"

29 September 2022

Holders should contact the following for further information:

The Dealer Managers and Solicitation Agents

Citigroup Global Markets Limited

Citigroup Centre

Canada Square

Canary Wharf

London E14 5LB

United Kingdom

Attention: Liability Management Group

Telephone: +44 20 7986 8969

Email: liabilitymanagement.europe@citi.com
(mailto:liabilitymanagement.europe@citi.com)

 

J.P. Morgan Securities plc
25 Bank Street

Canary Wharf

London E14 5JP

United Kingdom

Attention:  Liability Management

Telephone: +44 20 7134 2468

Email: em_europe_lm@jpmorgan.com (mailto:em_europe_lm@jpmorgan.com)

Société Générale

17 Cours Valmy

92987 Paris La Défense Cedex

France

Attention:  Liability Management

Telephone: +33 1 42 13 32 40

Email:  liability.management@sgcib.com
(mailto:liability.management@sgcib.com)

 

The Tender and Tabulation Agent:

Citibank, N.A., London Branch

Citigroup Centre

Canada Square

London E14 5LB

United Kingdom

 

 

Attention:  Tender Agent

Telephone: +44 20 7508 3867

Email:  citiexchanges@citi.com (mailto:citiexchanges@citi.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TENLLMITMTITBPT

Recent news on Natco Pharma

See all news